Moderna Inc has been asking sites that are conducting clinical trials of its experimental coronavirus vaccine to focus on enrolling at-risk minorities, even if that slows down the trial speed, the company said on Friday.Shares of Moderna, one of the few companies in the final stages of developing a safe and effective COVID-19 vaccine, closed down about 3.5%.The company said it has enrolled 21,411 participants in the study so far. It had 17,000 participants as of last week, with 24% from communities of color. console.log("catid body is "+catID);if(catID==120){document.getElementsByClassName("divConnatix")[0].style.display ="none";var script = document.createElement('script'); script.src = 'https://player.anyclip.com/anyclip-widget/lre-widget/prod/v1/src/lre.js'; script.setAttribute('pubname','jpostcom'); script.setAttribute('widgetname','0011r00001lcD1i_12258'); document.getElementsByClassName('divAnyClip')[0].appendChild(script);}else if(catID!=69 && catID!=2){ document.getElementsByClassName("divConnatix")[0].style.display ="none"; var script = document.createElement('script'); script.src = 'https://static.vidazoo.com/basev/vwpt.js'; script.setAttribute('data-widget-id','60fd6becf6393400049e6535'); document.getElementsByClassName('divVidazoo')[0].appendChild(script); }The drug developer aims to recruit 30,000 healthy volunteers and said it expected enrollment in the late-stage study, which began in late-July, to be completed in September.A growing body of evidence has shown that long-standing health and social inequities have resulted in increased risk of infection and death from COVID-19 among communities of color. Nearly a fifth of 11,000 people enrolled so far in a 30,000-volunteer U.S. trial testing a COVID-19 vaccine from Pfizer and German partner BioNTech are Black or Latino, groups among the hardest hit by the coronavirus, a top Pfizer executive told Reuters last month.